A Translational Approach to Predicting the Efficacy of Maraviroc-based Regimens as HIV Pre-exposure Prophylaxis.
Background: Maraviroc-based regimens have been explored as pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). Here we utilize mucosal tissue drug exposure data, combined with target concentrations generated in-vitro, in a pharmacokinetic/pharmacodynamic analysis to predict the effect of drug combinations and adherence on PrEP efficacy.Methods: Mucosal tissue concentrations of maraviroc were measured in 24 healthy women. The 90% effective concentration (EC90) of maraviroc (alone and combined with tenofovir and emtricitabine) for protection against HIV were identified in CD4+ T-cells. Monte Carlo simulations were performed to identify dosing strategies to protect colorectal and female genital tract (FGT) tissues from HIV infection.Results: Colorectal maraviroc concentrations were 350-fold higher than in the FGT. Under steady-state conditions, our model predicted that one 300 mg dose/week was sufficient to protect colorectal tissue from HIV in 99% of the population, while 300 mg daily would only protect the FGT in 63% of the population. FGT protection increased to >90% in combination with tenofovir (5 doses/week), or emtricitabine (3 doses/week).Conclusions: Poor adherence resulted in drastic decrease in efficacy in the FGT but not colorectal tissue. However, greater forgiveness was seen when maraviroc was combined with tenofovir or emtricitabine, suggesting that maraviroc should not be used alone as PrEP.